{"id":1032,"date":"2024-03-29T10:54:00","date_gmt":"2024-03-29T09:54:00","guid":{"rendered":"https:\/\/lensounds.com\/2024\/03\/29\/atonco-et-luniversite-du-michigan-annoncent-leur-collaboration-pour-letude-clinique-de-phase-1-2a-de-lato-101\/"},"modified":"2026-03-06T18:30:13","modified_gmt":"2026-03-06T17:30:13","slug":"atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101","status":"publish","type":"post","link":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/","title":{"rendered":"ATONCO AND THE UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION FOR THE PHASE 1-2a CLINICAL STUDY OF ATO-101\u2122"},"content":{"rendered":"\n<p>Atonco, a French biotechnology company, and the <strong>University of Michigan<\/strong> today announced a collaboration agreement to conduct a targeted alpha-therapy <strong>Phase 1-2a<\/strong> clinical study evaluating Atonco&#8217;s <strong>ATO-101\u2122 ([211At] anti-CA-IX antibody)<\/strong> in non-muscle-invasive bladder cancer (NMIBC).<\/p>\n\n\n\n<p>Bladder cancer is one of the most prevalent cancers worldwide, ranking 10th overall and 6th among men. In 2020, it accounted for more than 573,000 new cases and approximately 212,000 deaths globally.<\/p>\n\n\n\n<p>Although Bacillus Calmette-Gu\u00e9rin (BCG) therapy is the standard of care, it fails in approximately 40% of cases, leading to radical bladder removal procedures. While newer therapies such as immune checkpoint inhibitors have entered clinical trials, additional options are urgently needed.<\/p>\n\n\n\n<p>Atonco&#8217;s <strong>ATO-101\u2122 ([211At] anti-CA-IX antibody)<\/strong> is a targeted radiopharmaceutical composed of an alpha-emitting radionuclide, astatine-211 (211At), conjugated to the CAIX-specific monoclonal antibody Girentuximab (TLX250), designed to deliver the radioisotope directly to targeted cancer cells.<\/p>\n\n\n\n<p>The study will be led by <strong>Professor Benjamin Viglianti<\/strong>, in collaboration with <strong>Professor Peter Scott.<\/strong><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>&#8220;<em>The disruptive potential of targeted radiopharmaceutical therapies in cancer treatment is considerable, as these therapies have the ability to deliver radiation directly and specifically to cancer cells, potentially reducing, in our study, the risk of complications associated with traditional BCG therapy<\/em>,&#8221; noted Viglianti, Associate Professor of Clinical Radiology and Chief of the Division of Nuclear Medicine at the University of Michigan.<\/p><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>&#8220;<em>We are delighted to partner with the University of Michigan and leverage their world-class expertise in clinical radiopharmaceutical research to uncover the safety and activity profile of ATO-101\u2122. Atonco&#8217;s team will include Ms. Aur\u00e9lie Moreau and Mr. Denis Bilodeau, a seasoned expert leading our clinical research team in the United States and Europe<\/em>,&#8221; said Dr. Jean-Fran\u00e7ois Chatal, founder and Chief Medical Officer of Atonco.<\/p><\/blockquote>\n\n\n\n<p>The Phase 1-2a study will be conducted at the University of Michigan and will involve a number of satellite sites. Enrollment of the first study patients is expected to begin in the coming months, pending FDA approval of the study plan.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">About ATONCO<\/h3>\n\n\n\n<p>Atonco is a private company developing targeted radiopharmaceutical products for oncological applications. Originating from the nuclear medicine centre in Nantes, Atonco and its partners are committed to the clinical use of alpha-emitting radionuclides, particularly astatine-211.<\/p>\n\n\n\n<p>For more information, visit <a href=\"http:\/\/www.atonco-pharma.com\/\">www.atonco-pharma.com<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">About the UNIVERSITY OF MICHIGAN<\/h3>\n\n\n\n<p>The University of Michigan is a leading public research university committed to advancing knowledge and solving complex challenges. Its world-class faculty and state-of-the-art facilities make it a premier partner for medical research and clinical studies.<\/p>\n\n\n\n<p>For more information, visit <a href=\"https:\/\/umich.edu\">https:\/\/umich.edu<\/a><\/p>\n\n\n\n<p><a href=\"\/wp-content\/uploads\/2025\/11\/2024-03-29_ATONCO_University_Michigan.pdf\">PDF Version >><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Atonco, a French biotechnology company, and the University of Michigan today announced a collaboration agreement to conduct a targeted alpha-therapy Phase 1-2a clinical study evaluating Atonco&#8217;s ATO-101\u2122 ([211At] anti-CA-IX antibody) in non-muscle-invasive bladder cancer (NMIBC). Bladder cancer is one of the most prevalent cancers worldwide, ranking 10th overall and 6th among men. In 2020, it [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1034,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48],"tags":[],"class_list":["post-1032","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-atonco-press-releases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Atonco &amp; University of Michigan Launch Phase 1-2a Clinical Study of ATO-101\u2122<\/title>\n<meta name=\"description\" content=\"Atonco and University of Michigan partner to conduct Phase 1-2a clinical trial for ATO-101\u2122 in non-muscle-invasive bladder cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atonco &amp; University of Michigan Launch Phase 1-2a Clinical Study of ATO-101\u2122\" \/>\n<meta property=\"og:description\" content=\"Atonco and University of Michigan partner to conduct Phase 1-2a clinical trial for ATO-101\u2122 in non-muscle-invasive bladder cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-29T09:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-06T17:30:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/03\/michigan-800x350-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin27\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin27\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/\"},\"author\":{\"name\":\"admin27\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\"},\"headline\":\"ATONCO AND THE UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION FOR THE PHASE 1-2a CLINICAL STUDY OF ATO-101\u2122\",\"datePublished\":\"2024-03-29T09:54:00+00:00\",\"dateModified\":\"2026-03-06T17:30:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/\"},\"wordCount\":436,\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/michigan-800x350-1.png\",\"articleSection\":[\"Atonco press release\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/\",\"name\":\"Atonco & University of Michigan Launch Phase 1-2a Clinical Study of ATO-101\u2122\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/michigan-800x350-1.png\",\"datePublished\":\"2024-03-29T09:54:00+00:00\",\"dateModified\":\"2026-03-06T17:30:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\"},\"description\":\"Atonco and University of Michigan partner to conduct Phase 1-2a clinical trial for ATO-101\u2122 in non-muscle-invasive bladder cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/#primaryimage\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/michigan-800x350-1.png\",\"contentUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/michigan-800x350-1.png\",\"width\":800,\"height\":350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/03\\\/29\\\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ATONCO AND THE UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION FOR THE PHASE 1-2a CLINICAL STUDY OF ATO-101\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\",\"name\":\"admin27\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"caption\":\"admin27\"},\"sameAs\":[\"https:\\\/\\\/pulsheart-medical.com\"],\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/author\\\/admin27\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atonco & University of Michigan Launch Phase 1-2a Clinical Study of ATO-101\u2122","description":"Atonco and University of Michigan partner to conduct Phase 1-2a clinical trial for ATO-101\u2122 in non-muscle-invasive bladder cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/","og_locale":"en_US","og_type":"article","og_title":"Atonco & University of Michigan Launch Phase 1-2a Clinical Study of ATO-101\u2122","og_description":"Atonco and University of Michigan partner to conduct Phase 1-2a clinical trial for ATO-101\u2122 in non-muscle-invasive bladder cancer.","og_url":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/","og_site_name":"Atonco","article_published_time":"2024-03-29T09:54:00+00:00","article_modified_time":"2026-03-06T17:30:13+00:00","og_image":[{"width":800,"height":350,"url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/03\/michigan-800x350-1.png","type":"image\/png"}],"author":"admin27","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin27","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/#article","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/"},"author":{"name":"admin27","@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5"},"headline":"ATONCO AND THE UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION FOR THE PHASE 1-2a CLINICAL STUDY OF ATO-101\u2122","datePublished":"2024-03-29T09:54:00+00:00","dateModified":"2026-03-06T17:30:13+00:00","mainEntityOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/"},"wordCount":436,"image":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/03\/michigan-800x350-1.png","articleSection":["Atonco press release"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/","url":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/","name":"Atonco & University of Michigan Launch Phase 1-2a Clinical Study of ATO-101\u2122","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/#primaryimage"},"image":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/03\/michigan-800x350-1.png","datePublished":"2024-03-29T09:54:00+00:00","dateModified":"2026-03-06T17:30:13+00:00","author":{"@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5"},"description":"Atonco and University of Michigan partner to conduct Phase 1-2a clinical trial for ATO-101\u2122 in non-muscle-invasive bladder cancer.","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/#primaryimage","url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/03\/michigan-800x350-1.png","contentUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/03\/michigan-800x350-1.png","width":800,"height":350},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/2024\/03\/29\/atonco-university-michigan-collaboration-phase-1-2a-clinical-study-ato-101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"ATONCO AND THE UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION FOR THE PHASE 1-2a CLINICAL STUDY OF ATO-101\u2122"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5","name":"admin27","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","caption":"admin27"},"sameAs":["https:\/\/pulsheart-medical.com"],"url":"https:\/\/atonco-pharma.com\/en\/author\/admin27\/"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/comments?post=1032"}],"version-history":[{"count":17,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1032\/revisions"}],"predecessor-version":[{"id":1055,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1032\/revisions\/1055"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media\/1034"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/categories?post=1032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/tags?post=1032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}